

# Academic Public Private Partnership Program (AP4)

## SUCCESS STORY



### Impetus for AP4

Several progress review groups (PRGs) promoted the need for a new drug discovery and development assistance mechanism.

### Goal

To speed the translation of newly discovered cancer interventions to clinical trials.

### Advantages

#### Over NCDDG

- Requires multiple partners.
- Dynamic portfolio—projects can change.
- Opportunity for other government and charity funding combinations.

#### Over SBIR and STTR

- Big pharmaceutical companies can participate in AP4.

#### Over RAID, R\*A\*N\*D, and DDG

- Governance of projects is at academic center.
- Support is continual from discovery to late development as opposed to modular.

#### Over SPORES

- AP4 is not single-disease focused but can interact with SPORES and other cooperative groups.

### AP4 PLANNING GRANT AWARDS TO DATE

Investigator	Focus
Kevin Cullen, M.D., Greenebaum Cancer Center, University of Maryland	Orphan malignancies of the aerodigestive tract
Paul A. Bunn, M.D., University of Colorado	Development of therapeutic agents using individual tumor and tumor stroma data
Thomas V. O'Halloran, Ph.D., Northwestern University	Myeloma and pancreatic cancer
M. Sue O'Dorisio, M.D., University of Iowa Hospital and Clinic	Neuroendocrine tumors in both adults and children
Stephen B. Howell, M.D., University of California, San Diego	Novel molecular imaging technology and tumor-specific drug delivery
Stephen W. Morris, M.D., St. Jude Children's Research Hospital	Novel therapies for "double orphan" or pediatric cancers
Gregory Sorensen, M.D., Massachusetts General Hospital	Imaging biomarkers
Larry A. Couture, Ph.D., City of Hope National Medical Center	Advanced cellular/immuno therapies
Ronald B. Herberman, M.D., University of Pittsburgh Cancer Institute	Inhibitors of phosphatases and utilization of anti-idiotypic antibodies
Tom Mikkelsen, M.D., Case Western Reserve University, Henry Ford Hospital	Glioblastoma multiforme therapies and diagnostics
Kit S. Lam, M.D., Ph.D., University of California, Davis	Acute myelocytic leukemia and acute lymphocytic leukemia
Anatoly Dritschilo, M.D., Georgetown University Medical Center	Molecular targets for radiation sensitization of cancers
Bruce Boman, M.D., Thomas Jefferson University	Hereditary colorectal cancer
Herbert Lyerly, M.D., Duke University Medical Center	Cancer immunotherapy

### AP4 TIMELINE

Date	Milestone
2001	Discussion with OSPA, PRG, DTP, CTEP, and OGC
2002	July: Preliminary consultation with the Director of NCI
	August: Discussion with NDC members
October	Discussion with PRG/LLM
	• Grain size of NCI commitment • Clinical vs. preclinical focus
November	Discussion with Leukemia & Lymphoma Society
December	Input from EC
2003	February: Presentation to EC
	March: Presentation to BSA
April	AACR; publicize program to investigator community
July	Appears in <i>NIH Guide</i>
November	Receipt of 38 planning grant applications
2004	March: Review of planning grant applications
	July: Award of 14 planning grants
September	Notice of AP4 Center grant; RFA sent to planning grant PIs
2005	June: Receipt of AP4 Center applications
	August: Review of applications
	December: NCAB funding approval
2006	February: Award 4 to 6 AP4 Center grants; Projected cost: \$4.7 M